Side-by-Side Comparison
Ipamorelin vs MK-677: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Ipamorelin and MK-677 differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
MK-677
L4Also: Ibutamoren, Nutrobal, L-163,191
An oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. Has extensive human data but has not achieved FDA approval.
Side-by-side comparison
| Attribute | Ipamorelin | MK-677 |
|---|---|---|
| Primary mechanism | Ghrelin Receptor Agonism | Oral Ghrelin Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | Research Only |
| Evidence level | Emerging Clinical Evidence | Strong Clinical Evidence |
| Human trials | Yes (2+ indexed) | Yes (15+ indexed) |
| Studies indexed | 33 total (4 human, 18 animal) | 75 total (25 human, 30 animal) |
| Primary uses researched | Growth hormone release, Body composition, Sleep quality, Recovery | Growth hormone release, Sleep quality, Appetite stimulation, Bone density (research) |
| Administration routes | subcutaneous | oral |
| Molecular weight | 711.85 Da | 528.67 Da |
| Amino acids | 5 | — |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Both compounds share the same primary mechanism (ghrelin receptor agonism), so differences between them are driven by pharmacokinetics, selectivity, and clinical data rather than mechanism class.
Regulatory status. Ipamorelin is classified as banned from compounding (category 2); MK-677 is classified as research only. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. MK-677 sits at a higher evidence level (L4) than Ipamorelin (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Ipamorelin has concentrated on growth hormone release, body composition, sleep quality. Research on MK-677 has concentrated on growth hormone release, sleep quality, appetite stimulation. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Ipamorelin | MK-677 |
|---|---|---|
| Documented effects | 6 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 1 | 4 |
| Black box warning | No | No |
| Contraindications | 3 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Increased appetite |
Strengths & limitations
Ipamorelin
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
MK-677
Strengths
- Strong evidence base (L4)
- Multiple human clinical trials (15+ indexed)
Limitations
- Not FDA-approved for any indication — research use only
- Prohibited in competitive sport under WADA
Representative studies
Ipamorelin
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone release in a specific and selective manner
Raun K, Hansen BS, Johansen NL, et al. · Journal of Endocrinology (1998)
Ipamorelin demonstrated true GH selectivity: no cortisol/ACTH/prolactin elevation even at supramaximal doses, establishing it as the cleanest GHRP.
PubMed 9725926Ipamorelin, the first selective growth hormone secretagogue
Johansen PB, Nowak J, Skjærbæk C, et al. · European Journal of Endocrinology (1999)
Confirmed ipamorelin as the first truly selective GH secretagogue, with a selectivity window exceeding 200-fold between GH release and cortisol stimulation.
PubMed 10580762MK-677
MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism
Murphy MG, Plunkett LM, Gertz BJ, et al. · Journal of Clinical Endocrinology & Metabolism (1998)
MK-677 25mg daily reversed diet-induced nitrogen wasting by increasing GH pulse amplitude and IGF-1 levels.
PubMed 9467534Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial
Nass R, Pezzoli SS, Oliveri MC, et al. · Annals of Internal Medicine (2008)
MK-677 increased GH and IGF-1 to youthful levels for 12 months but did not improve strength or function, and insulin sensitivity declined significantly.
PubMed 18981485Frequently asked
What is the main difference between Ipamorelin and MK-677?
Ipamorelin is a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. Its primary mechanism is ghrelin receptor agonism. MK-677 is an oral ghrelin mimetic (not a peptide) that stimulates growth hormone release. has extensive human data but has not achieved fda approval. Its primary mechanism is oral ghrelin receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs Research Only), strength of evidence (L3 vs L4), and the primary conditions for which each is researched.
Is Ipamorelin or MK-677 FDA approved?
Ipamorelin: Placed on FDA Category 2 list in late 2023. Not approved for human use. MK-677: Not FDA-approved. Non-peptide ghrelin mimetic (not technically a peptide, but commonly grouped with peptides). Has failed in clinical trials for growth hormone deficiency.
How does the evidence base compare?
Ipamorelin has 33 indexed studies (4 human, 18 animal) and is rated Emerging Clinical Evidence. MK-677 has 75 indexed studies (25 human, 30 animal) and is rated Strong Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Ipamorelin and MK-677 be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Ipamorelin and MK-677 commonly stacked together?
There is no widely documented stacking protocol combining Ipamorelin and MK-677 in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Ipamorelin or MK-677?
Ipamorelin has 6 documented side effects (0 serious). MK-677 has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Ipamorelin and MK-677 administered?
Ipamorelin is typically administered via subcutaneous. MK-677 is typically administered via oral. Route differences affect onset, peak levels, and patient convenience.
Which is better, Ipamorelin or MK-677?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Ipamorelin is most researched for growth hormone release and body composition; MK-677 is most researched for growth hormone release and sleep quality. FDA status also matters: Banned from Compounding (Category 2) for Ipamorelin vs Research Only for MK-677. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Ipamorelin →
Full profile
MK-677 →